Analysis of the economically justifiable price of nirsevimab to prevent respiratory syncytial virus infection in Korea

The current standard-of-care prophylaxis for respiratory syncytial virus (RSV) is primarily administered to high-risk infant populations. We conducted a cost-effectiveness analysis to determine the economically justifiable price of nirsevimab compared with the standard of care in preventing medicall...

Full description

Bibliographic Details

Published in:	Human Vaccines & Immunotherapeutics
Main Authors:	Hyun Jin Han, Semin Jang, Ryu Dahye, Haeseon Lee, Jiyeon Lee, Eun Jin Bae, Samira Soudani, Hae Sun Suh
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2025-12-01
Subjects:	Respiratory syncytial virus nirsevimab cost-effectiveness analysis
Online Access:	https://www.tandfonline.com/doi/10.1080/21645515.2025.2545637